OpenEvidence Secures $210 Million Series B Funding, Achieves $3.5 Billion Valuation
OpenEvidence, a leading clinical decision AI platform, today announced the closing of its $210 million Series B funding round, co-led by GV and Kleiner Perkins. This investment raises the company’s valuation to $3.5 billion and brings its total funding to over $300 million.
Founded in 2021 by Daniel Nadler and Zachary Ziegler, OpenEvidence provides verified physicians with an advanced medical search platform that delivers fully cited answers from a database of over 35 million peer-reviewed publications in just seconds. The platform is now used daily by more than 40% of U.S. physicians, serving over 10,000 hospitals and medical centers nationwide.
Alongside the funding announcement, OpenEvidence unveiled DeepConsult, an AI-powered autonomous agent designed to synthesize complex research into clear, actionable medical briefs. The tool is currently available at no cost to licensed clinicians in the United States.
The new capital will be used to expand product development, enhance AI capabilities, and strengthen partnerships with leading medical publishers. It will also support the company’s mission to make accurate, up-to-date medical knowledge instantly accessible to clinicians worldwide.
Daniel Nadler, Co-Founder and CEO of OpenEvidence, stated: “This investment marks a pivotal step in our mission to empower every physician with the most reliable, evidence-based medical information in real time.”
With strong adoption rates, robust partnerships, and cutting-edge AI tools, OpenEvidence is positioning itself as a transformative force in global healthcare.
